A Phase 3 interventional study of Emtricitabine (FTC) and Tenofovir Disoproxil Fumarate (TDF) in HIV Infections, sponsored by Gilead Sciences. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-10-13.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing emtricitabine in HIV Infections — 4 open to participants now, 8 under way, 4 of them phase 3. Emtricitabine · HIV Infections.
Among the 65 studies testing emtricitabine in HIV Infections, this one is the 12th largest by enrollment of the 63 interventional ones that give a count, is the only one that started in 2003, is one of 17 in phase 3, and was the 11th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 65 studies testing emtricitabine in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
CAN Community Health · Sites in United States
Ages 18+
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+ · Men only
University College, London
Ages 4 wk–14 yrs
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
Emtricitabine: first FDA approval 2003 (EMTRIVA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 19 · Phase 4 22
First in 1999; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 517 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 100 across the 63 interventional studies. Of the 48 that completed or were terminated, 22 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 65 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 13th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2003, is one of 26 in phase 3, and was the 32nd registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
1 of the studies testing emtricitabine in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476339CAN Community HealthREINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | 2027-06-17 |
Add it to your calendar (.ics) → With an account.
Among the 65 studies testing emtricitabine in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants. The primary objective of the study was to assess noninferiority of emtricitabine (FTC) and tenofovir disoproxil fumarate (tenofovir DF; TDF) in combination with efavirenz (EFV) relative to Combivir (CBV) in combination with EFV in the treatment of HIV-1 infected ART-naive participants, determined by the achievement and maintenance of confirmed HIV-1 ribonucleic acid (RNA) \< 400 copies/mL (c/mL) through Week 48, as defined by the United States (US) Food and Drug Administration (FDA) time-to-loss-of-virologic-response (TLOVR) algorithm.
This study was originally planned as a 48-week, Phase 3, randomized, open-label, multicenter study comparing EFV+FTC+TDF (administered as the individual component drugs) versus CBV (lamivudine/zidovudine) + EFV to assess the efficacy and safety of both treatments in ART-Naive, HIV-1 infected participants. The regimen of CBV (administered twice daily) + EFV (administered once daily) served as the active control treatment and was compared with the regimen of EFV+FTC+TDF; each component drug in the EFV+FTC+TDF regimen was administered once daily.
Week 48 to Week 96:
The study was extended and continued to evaluate the efficacy and safety of the two regimens up to a total treatment duration of 96 weeks. The regimen of EFV+FTC+TDF continued to be dosed as the component drugs (EFV + FTC + TDF), once daily, without regard to meals. The regimen of CBV+EFV was dosed as 2 pills (CBV, twice daily in the morning without regard to meals) + EFV (once daily, without regard to meals).
Week 96 to Week 144:
A further study extension changed the 3-pill EFV+FTC+TDF regimen to a 2-pill regimen of EFV + Truvada ([TVD]: a fixed-dose combination pill containing FTC/TDF), once daily without regard to meals, and continued to evaluate the efficacy and safety of the two regimens for a further 48 weeks up to a total study treatment duration of 144 weeks. The regimen of CBV+EFV continued to be dosed as 2 pills (CBV, twice daily in the morning without regard to meals) + EFV (once daily, without regard to meals).
Week 144 to end of study (Week 240):
A final study extension provided all study participants from both treatment regimens the option to switch their respective treatments to the 1-pill regimen of for a further 96 weeks up to a total study duration of 240 weeks (5 years) to further assess the efficacy and safety of ART regimen simplification. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:
Exclusion Criteria: Participants were not eligible for entry to the study if any of the following were met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group received EFV 600 mg once daily + Combivir (\[CBV\]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla (\[ATR\]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
Drug: Efavirenz (EFV) · Drug: Lamivudine/zidovudine
Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF \[TDF\]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada (\[TVD\] the fixed-dose combination pill containing FTC/TDF \[200/300 mg\] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
Drug: Emtricitabine (FTC) · Drug: Tenofovir Disoproxil Fumarate (TDF) · Drug: Efavirenz (EFV) · Drug: FTC/TDF · Drug: FTC/TDF/EFV
Capsule containing 200 mg FTC, taken once daily, for 96 weeks
Also known as: Emtriva
Tablet containing 300 mg TDF, taken once daily, for 96 weeks
Also known as: Viread
Tablet containing 600 mg EFV, taken once daily, for 96 weeks
Also known as: Sustiva
Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
Also known as: Truvada (TVD)
Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
Also known as: Atripla (ATR)
Drug pages: Lamivudine · Zidovudine
Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
Also known as: Combivir (CBV)
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 48 visit (ie, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 48 visit.
Time frame: 48 weeks
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm)
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 48 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 48 visit.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48.
The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).
Time frame: 48 weeks
Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48
The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).
Time frame: 48 Weeks
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Baseline to 48 weeks
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Baseline to 48 Weeks
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Baseline to 48 Weeks
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Baseline to 48 Weeks
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48
Change from study baseline to Week 48 in HIV-1 RNA in log10 scale (Week 48 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).
Time frame: Study baseline to Week 48
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48
Change from study baseline to Week 48 in CD4 cell count = Week 48 CD4 cell count value minus study baseline CD4 cell count value
Time frame: Study baseline to Week 48
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 96 visit.
Time frame: 96 Weeks
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm)
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 96 visit.
Time frame: Week 96
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96
TLOVR for participants with confirmed virologic response (2 consecutive HIV-1 RNA \< 400 c/mL) prior to study drug discontinuation, was the time to the earliest of premature study regimen discontinuation, or confirmed HIV-1 RNA \> 400 c/mL (2 consecutive HIV-1 RNA ≥ 400 c/mL, or the last HIV-1 RNA ≥ 400 c/mL followed by premature study regimen discontinuation due to loss to follow-up). Participants who did not achieve confirmed virologic response before premature study regimen discontinuation or last HIV-1 RNA, were assumed to have lost virologic response on Study Day 1.
Time frame: Week 96
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Week 96
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Week 96
Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Week 96
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96
Change from study baseline to Week 96 in HIV-1 RNA in log10 scale (Week 96 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).
Time frame: Study baseline to Week 96
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96
Change from study baseline to Week 96 in CD4 cell count = Week 96 CD4 cell count value minus study baseline CD4 cell count value
Time frame: Baseline to Week 96
Change in Limb Fat (kg) From Week 48 to Week 96
Change from Week 48 to Week 96 in limb fat = Week 96 limb fat value minus Week 48 limb fat value.
Time frame: Week 48 to Week 96
Change in Trunk Fat (kg) From Week 48 to Week 96
Change from Week 48 to Week 96 in trunk fat = Week 96 trunk fat value minus Week 48 trunk fat value
Time frame: Week 48 to Week 96
Change in Total Body Fat (kg) From Week 48 to Week 96
Change from Week 48 to Week 96 in total body fat = Week 96 total body fat value minus Week 48 total body fat value
Time frame: 48 weeks to 96 weeks
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 144 visit (i.e., the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV-1 RNA levels \< 400 c/mL prior to Week 144 visit.
Time frame: 144 weeks
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm)
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL (c/mL) had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 144 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV-1 RNA levels \< 50 c/mL prior to Week 144 visit.
Time frame: Week 144
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144
The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).
Time frame: Week 144
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144
The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).
Time frame: Week 144
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Week 144
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Week 144
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Week 144
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Week 144
Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144
Change from study baseline to Week 144 in HIV-1 RNA in log10 scale (Week 144 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).
Time frame: Study baseline to Week 144
Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144
Change from study baseline to Week 144 in CD4 cell count = Week 144 CD4 cell count value minus study baseline CD4 cell count value
Time frame: Baseline to Week 144
Change in Limb Fat (kg) From Week 48 to Week 144
Change from Week 48 to Week 144 in limb fat = Week 144 limb fat value minus Week 48 limb fat value
Time frame: Week 48 to Week 144
Change in Trunk Fat (kg) From Week 48 to Week 144
Change from Week 48 to Week 144 in trunk fat = Week 144 trunk fat value minus Week 48 trunk fat value
Time frame: Week 48 to Week 144
Change in Total Body Fat (kg) From Week 48 to Week 144
Change from Week 48 to Week 144 in total body fat = Week 144 total body fat value minus Week 48 total body fat value
Time frame: Week 48 to Week 144
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 240 visit.
Time frame: Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 240 visit.
Time frame: Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)
Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96)
The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).
Time frame: Week 240 (Atripla Week 96)
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96)
The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).
Time frame: Week 240 (Atripla Week 96)
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96)
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96)
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Week 240 (Atripla Week 96)
Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96)
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
Time frame: Week 240 (Atripla Week 96)
Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96)
Change from baseline to Week 240 (Atripla Week 96) in CD4 cell count = Week 240 (Atripla Week 96) CD4 cell count value minus baseline CD4 cell count value
Time frame: Study/Atripla baseline to Week 240 (Atripla Week 96)
Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in limb fat = Week 240 (Atripla Week 96) limb fat value minus Week 144 (Atripla Baseline) limb fat value
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in trunk fat = Week 240 (Atripla Week 96) trunk fat value minus Week 144 (Atripla Baseline) trunk fat value
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in total body fat = Week 240 (Atripla Week 96) total body fat value minus Week 144 (Atripla Baseline) total body fat value
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
Participants were asked: "In general, how satisfied are you with the convenience and simplicity of your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
Participants were asked: "In general, how satisfied are you with the ability of your current treatment regimen to control your HIV infection?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
Participants were asked: "In general, how satisfied are you with your ability to tolerate your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
Participants were asked: "In general, how satisfied are you with your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.
Participants were asked: "How bothered are you with the side effects of your current treatment regimen?" Possible responses were on a 4-category scale: "does not bother me"; "bothers me a little bit"; "bothers me a lot"; and "bothers me terribly". For the evaluation of the change in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "does not bother me" and "bothers me" ("bothers me" included "bothers me a little bit"; "bothers me a lot"; "bothers me terribly").
Time frame: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey: Physical Component Summary (PCS). The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the Mental Component Summary (MCS). PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and SD of 10 (in the general population).
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey MCS. The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the MCS. PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and a SD of 10 (in the general population).
Time frame: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
Participants were enrolled at 70 study sites in the United States and Europe. The first participant was screened on 29 July 2003; the last participant was randomized on 16 January 2004; the last participant observation for the primary endpoint analysis was 11 February 2005; the last participant last visit for end of study analysis was 10 June 2009.
| Milestone | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Started | 257 | 254 |
| Completed | 187 | 166 |
| Not completed | 70 | 88 |
| Withdrew: Lost to follow-up | 26 | 33 |
| Withdrew: Adverse event | 10 | 10 |
| Withdrew: Withrawal of consent | 10 | 18 |
| Withdrew: Sub-optimal virological response | 3 | 13 |
| Withdrew: Noncompliance | 8 | 4 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Pregnancy | 3 | 1 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Hepatitis c treatment contraindicated | 0 | 1 |
| Withdrew: Inability to swallow pills | 0 | 1 |
| Withdrew: Incarceration | 3 | 2 |
| Withdrew: Moved out of state | 0 | 1 |
| Withdrew: Baseline nnrti resistance mutations | 4 | 0 |
| Withdrew: High hepatitis b dna | 0 | 1 |
| Milestone | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Started | 160 | 126 |
| Completed | 142 | 106 |
| Not completed | 18 | 20 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lost to follow-up | 5 | 7 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Withdrew consent | 7 | 7 |
| Withdrew: Sub-optimal virological response | 0 | 1 |
| Withdrew: Non-compliance | 1 | 0 |
| Withdrew: Other | 3 | 1 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 48 visit (ie, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 48 visit.
| Percentage of participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm | 84.4 | 72.8 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 48 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 48 visit.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm) | 79.5 | 70.4 |
The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 48. | 80.4 | 69.3 |
The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 c/mL at Week 48 | 74.5 | 66.9 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 48 | 19 | 30 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 48 | 23 | 32 |
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 48 | 9 | 16 |
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 48 | 16 | 24 |
Change from study baseline to Week 48 in HIV-1 RNA in log10 scale (Week 48 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).
| Log10 c/mL | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48 | -3.31 ± 0.54 | -3.26 ± 0.58 |
Change from study baseline to Week 48 in CD4 cell count = Week 48 CD4 cell count value minus study baseline CD4 cell count value
| CD4 Cell Count (cells/mm^3) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48 | 190 ± 111.7 | 158 ± 107.3 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 96 visit.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm) | 74.6 | 61.9 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 96 visit.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm) | 67.2 | 60.9 |
TLOVR for participants with confirmed virologic response (2 consecutive HIV-1 RNA \< 400 c/mL) prior to study drug discontinuation, was the time to the earliest of premature study regimen discontinuation, or confirmed HIV-1 RNA \> 400 c/mL (2 consecutive HIV-1 RNA ≥ 400 c/mL, or the last HIV-1 RNA ≥ 400 c/mL followed by premature study regimen discontinuation due to loss to follow-up). Participants who did not achieve confirmed virologic response before premature study regimen discontinuation or last HIV-1 RNA, were assumed to have lost virologic response on Study Day 1.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 96 | 25 | 37 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 96 | 32 | 38 |
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 400 c/mL) at Week 96 | 9 | 17 |
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Pure Virologic Failure (HIV-1 RNA < 50 c/mL) at Week 96 | 20 | 23 |
Change from study baseline to Week 96 in HIV-1 RNA in log10 scale (Week 96 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).
| Log10 c/mL | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96 | -3.30 ± 0.57 | -3.25 ± 0.59 |
Change from study baseline to Week 96 in CD4 cell count = Week 96 CD4 cell count value minus study baseline CD4 cell count value
| CD4 Cell Count (cells/mm^3) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96 | 270 ± 147.5 | 237 ± 136.4 |
Change from Week 48 to Week 96 in limb fat = Week 96 limb fat value minus Week 48 limb fat value.
| limb fat (kg) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change in Limb Fat (kg) From Week 48 to Week 96 | 0.74 ± 1.60 | -0.77 ± 1.58 |
Change from Week 48 to Week 96 in trunk fat = Week 96 trunk fat value minus Week 48 trunk fat value
| trunk fat (kg) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change in Trunk Fat (kg) From Week 48 to Week 96 | 0.94 ± 2.30 | -0.04 ± 1.65 |
Change from Week 48 to Week 96 in total body fat = Week 96 total body fat value minus Week 48 total body fat value
| total body fat (kg) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change in Total Body Fat (kg) From Week 48 to Week 96 | 1.69 ± 3.80 | -0.82 ± 3.01 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 144 visit (i.e., the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV-1 RNA levels \< 400 c/mL prior to Week 144 visit.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm) | 70.9 | 58.1 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL (c/mL) had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 144 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV-1 RNA levels \< 50 c/mL prior to Week 144 visit.
| Percentage of participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm) | 64.3 | 56.3 |
The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 144 | 63.1 | 51.6 |
The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 144 | 60.8 | 50.4 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) at Week 144 | 28 | 41 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) at Week 144 | 34 | 43 |
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) at Week 144 | 11 | 17 |
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of Participants | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) at Week 144 | 21 | 25 |
Change from study baseline to Week 144 in HIV-1 RNA in log10 scale (Week 144 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale).
| Log10 c/mL | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144 | -3.32 ± 0.54 | -3.30 ± 0.52 |
Change from study baseline to Week 144 in CD4 cell count = Week 144 CD4 cell count value minus study baseline CD4 cell count value
| CD4 Cell Count (cells/mm^3) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144 | 312 ± 161.2 | 271 ± 147.4 |
Change from Week 48 to Week 144 in limb fat = Week 144 limb fat value minus Week 48 limb fat value
| limb fat (kg) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change in Limb Fat (kg) From Week 48 to Week 144 | 1.13 ± 1.93 | -1.09 ± 1.72 |
Change from Week 48 to Week 144 in trunk fat = Week 144 trunk fat value minus Week 48 trunk fat value
| trunk fat (kg) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change in Trunk Fat (kg) From Week 48 to Week 144 | 1.30 ± 2.40 | -0.10 ± 1.79 |
Change from Week 48 to Week 144 in total body fat = Week 144 total body fat value minus Week 48 total body fat value
| total body fat (kg) | EFV+FTC+TDF | CBV+EFV |
|---|---|---|
| Change in Total Body Fat (kg) From Week 48 to Week 144 | 2.47 ± 4.22 | -1.18 ± 3.37 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 400 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 400 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 400 c/mL after achievement of confirmed HIV RNA levels \< 400 c/mL prior to Week 240 visit.
| Percentage of Participants | All Atripla |
|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm | 87 |
Participants who achieved/maintained confirmed HIV-1 RNA \< 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA \< 50 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA \< 50 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA \> 50 c/mL after achievement of confirmed HIV RNA levels \< 50 c/mL prior to Week 240 visit.
| Percentage of Participants | All Atripla |
|---|---|
| Percentage of Participants With Confirmed Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm | 85 |
The percentage of participants with plasma HIV-1 RNA \< 400 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis).
| Percentage of Participants | EFV+FTC+TDF/Atripla (From Study Baseline) | All Atripla (From Atripla Baseline) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA < 400 c/mL at Week 240 (Atripla Week 96) | 87 | 85 |
The percentage of participants with plasma HIV-1 RNA \< 50 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis).
| Percentage of Participants | EFV+FTC+TDF/Atripla (From Study Baseline) | All Atripla (From Atripla Baseline) |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Week 240 (Atripla Week 96) | 84 | 82 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | All Atripla |
|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96) | 13 |
TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered "non-responders" on Study Day 1.
| Percentage of Participants | All Atripla |
|---|---|
| Percentage of Participants With Loss of Virologic Response (HIV-1 RNA < 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96) | 15 |
Participants who achieved confirmed HIV-1 RNA \< 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of Participants | EFV+FTC+TDF/Atripla (From Study Baseline) | All Atripla (From Atripla Baseline) |
|---|---|---|
| Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 400 c/mL) Through Week 240 (Atripla Week 96) | 11 | 2 |
Participants who achieved confirmed HIV-1 RNA \< 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date.
| Percentage of Participants | EFV+FTC+TDF/Atripla (From Study Baseline) | All Atripla (From Atripla Baseline) |
|---|---|---|
| Percentage of Participants With Pure Virological Failure (HIV-1 RNA < 50 c/mL) Through Week 240 (Atripla Week 96) | 22 | 4 |
Change from baseline to Week 240 (Atripla Week 96) in CD4 cell count = Week 240 (Atripla Week 96) CD4 cell count value minus baseline CD4 cell count value
| CD4 Cell count (Cells/mm^3) | EFV+FTC+TDF/Atripla (From Study Baseline) | All Atripla (From Atripla Baseline) |
|---|---|---|
| Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96) | 346 ± 197.2 | 42 ± 148.2 |
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in limb fat = Week 240 (Atripla Week 96) limb fat value minus Week 144 (Atripla Baseline) limb fat value
| limb fat (kg) | All Atripla |
|---|---|
| Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) | 0.12 ± 1.657 |
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in trunk fat = Week 240 (Atripla Week 96) trunk fat value minus Week 144 (Atripla Baseline) trunk fat value
| trunk fat (kg) | All Atripla |
|---|---|
| Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) | 0.27 ± 2.242 |
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in total body fat = Week 240 (Atripla Week 96) total body fat value minus Week 144 (Atripla Baseline) total body fat value
| total body fat (kg) | All Atripla |
|---|---|
| Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) | 0.37 ± 3.747 |
Participants were asked: "In general, how satisfied are you with the convenience and simplicity of your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
| Participants | All Atripla |
|---|---|
| Very satisfied (W 144 and W 240) | 182 |
| Not very satisfied (W 144 and W 240) | 6 |
| Very satisfied (W 144); not very satisfied (W 240) | 8 |
| Not very satisfied (W 144); very satisfied (W 240) | 29 |
Participants were asked: "In general, how satisfied are you with the ability of your current treatment regimen to control your HIV infection?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
| Participants | All Atripla |
|---|---|
| Very satisfied (W 144 and W 240) | 192 |
| Not very satisfied (W 144 and W 240) | 8 |
| Very satisfied (W 144); not very satisfied (W 240) | 9 |
| Not very satisfied (W 144); very satisfied (W 240) | 17 |
Participants were asked: "In general, how satisfied are you with your ability to tolerate your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
| Participants | All Atripla |
|---|---|
| Very satisfied (W 144 and W 240) | 166 |
| Not very satisfied (W 144 and W 240) | 21 |
| Very satisfied (W 144); not very satisfied (W 240) | 13 |
| Not very satisfied (W 144); very satisfied (W 240) | 26 |
Participants were asked: "In general, how satisfied are you with your current treatment regimen?" Possible responses were on a 4-category scale: "very satisfied"; "somewhat satisfied"; "somewhat dissatisfied"; and "very dissatisfied". For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "very satisfied" and "not very satisfied" ("not very satisfied" included "very dissatisfied"; "somewhat dissatisfied"; and "somewhat satisfied").
| Participants | All Atripla |
|---|---|
| Very satisfied (W 144 and W 240) | 180 |
| Not very satisfied (W 144 and W 240) | 10 |
| Very satisfied (W 144); not very satisfied (W 240) | 9 |
| Not very satisfied (W 144); very satisfied (W 240) | 23 |
Participants were asked: "How bothered are you with the side effects of your current treatment regimen?" Possible responses were on a 4-category scale: "does not bother me"; "bothers me a little bit"; "bothers me a lot"; and "bothers me terribly". For the evaluation of the change in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into "does not bother me" and "bothers me" ("bothers me" included "bothers me a little bit"; "bothers me a lot"; "bothers me terribly").
| Participants | All Atripla |
|---|---|
| Bothers me (W 144 and W 240) | 41 |
| Does not bother me (W 144 and W 240) | 126 |
| Bothers me (W 144); does not bother me (W 240) | 31 |
| Does not bother me (W 144); bothers me (W 240) | 28 |
The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey: Physical Component Summary (PCS). The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the Mental Component Summary (MCS). PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and SD of 10 (in the general population).
| Composite Score | All Atripla |
|---|---|
| Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) | 0.0 ± 6.80 |
The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey MCS. The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the MCS. PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and a SD of 10 (in the general population).
| Composite Score | All Atripla |
|---|---|
| Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) | 0.9 ± 8.65 |
Collected over Adverse events (AEs) were reported during the 144-week randomized treatment phase (FTC+TDF+EFV and CBV+EFV groups) and for the 96-week non-randomized Atripla extension phase (for all participants who opted to switch to Atripla).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FTC+TDF+EFV (Baseline to 144 Weeks) | — | 29/257 (11.3%) | 233/257 (90.7%) |
| FTC+TDF+EFV/ATR (Baseline to 240 Weeks) | — | 24/160 (15%) | 152/160 (95%) |
| CBV+EFV (Baseline to 144 Weeks) | — | 35/254 (13.8%) | 222/254 (87.4%) |
| All Atripla (Week 144 to 240) | — | 14/286 (4.9%) | 190/286 (66.4%) |
| Event | FTC+TDF+EFV (Baseline to 144 Weeks) | FTC+TDF+EFV/ATR (Baseline to 240 Weeks) | CBV+EFV (Baseline to 144 Weeks) | All Atripla (Week 144 to 240) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/257 | 0/160 | 7/254 | 0/286 |
| PneumoniaInfections and infestations | 2/257 | 3/160 | 2/254 | 1/286 |
| AppendicitisInfections and infestations | 2/257 | 2/160 | 2/254 | 0/286 |
| NephrolithiasisRenal and urinary disorders | 2/257 | 2/160 | 0/254 | 0/286 |
| Subcutaneous AbscessInfections and infestations | 0/257 | 2/160 | 0/254 | 2/286 |
| Staphylococcal AbscessInfections and infestations | 0/257 | 0/160 | 2/254 | 0/286 |
| AlcoholismPsychiatric disorders | 1/257 | 1/160 | 0/254 | 0/286 |
| Anal Cancer MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/257 | 1/160 | 0/254 | 1/286 |
| Benign Prostatic HyperplasiaReproductive system and breast disorders | 0/257 | 1/160 | 0/254 | 1/286 |
| Dental CariesGastrointestinal disorders | 1/257 | 1/160 | 0/254 | 0/286 |
| Event | FTC+TDF+EFV (Baseline to 144 Weeks) | FTC+TDF+EFV/ATR (Baseline to 240 Weeks) | CBV+EFV (Baseline to 144 Weeks) | All Atripla (Week 144 to 240) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 73/257 | 57/160 | 50/254 | 29/286 |
| NauseaGastrointestinal disorders | 66/257 | 37/160 | 83/254 | 6/286 |
| DizzinessNervous system disorders | 71/257 | 50/160 | 74/254 | 9/286 |
| NasopharyngitisInfections and infestations | 45/257 | 49/160 | 33/254 | 42/286 |
| Upper Respiratory Tract InfectionInfections and infestations | 48/257 | 49/160 | 27/254 | 30/286 |
| HeadacheNervous system disorders | 51/257 | 40/160 | 43/254 | 16/286 |
| InsomniaPsychiatric disorders | 44/257 | 38/160 | 45/254 | 22/286 |
| SinusitisInfections and infestations | 33/257 | 35/160 | 17/254 | 19/286 |
| FatigueGeneral disorders | 46/257 | 34/160 | 46/254 | 14/286 |
| Abnormal DreamsPsychiatric disorders | 45/257 | 33/160 | 34/254 | 3/286 |
| Age Continuous(years) | EFV+FTC+TDF | CBV+EFV | Total |
|---|---|---|---|
| Mean | 38 ± 9.9 | 38 ± 9.0 | 38 ± 9.5 |
| Sex: Female, Male(Participants) | EFV+FTC+TDF | CBV+EFV | Total |
|---|---|---|---|
| Female | 36 | 33 | 69 |
| Male | 219 | 221 | 440 |
| Race/Ethnicity, Customized(Participants) | EFV+FTC+TDF | CBV+EFV | Total |
|---|---|---|---|
| White | 142 | 156 | 298 |
| Black | 65 | 51 | 116 |
| Hispanic | 39 | 40 | 79 |
| Asian | 3 | 3 | 6 |
| Not allowed to report | 0 | 1 | 1 |
| Other | 6 | 3 | 9 |
| HIV Status(Participants) | EFV+FTC+TDF | CBV+EFV | Total |
|---|---|---|---|
| Asymptomatic | 33 | 26 | 59 |
| Symptomatic HIV Infection | 117 | 127 | 244 |
| AIDS | 105 | 101 | 206 |
| CD4 cell count(Cells/mm^3) | EFV+FTC+TDF | CBV+EFV | Total |
|---|---|---|---|
| Mean | 246 ± 171.9 | 245 ± 156.6 | 245 ± 164.2 |
| HIV-1 RNA(Log10 c/mL) | EFV+FTC+TDF | CBV+EFV | Total |
|---|---|---|---|
| Mean | 5.03 ± 0.54 | 5.00 ± 0.51 | 5.01 ± 0.52 |
The record gives a start of Jul 2003, a primary completion of Feb 2005 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emtricitabine · Tenofovir